Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group.

@article{Hogg2006ClinicalTT,
  title={Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group.},
  author={Ronald J. Hogg and Jeannette L Lee and Nancy Nardelli and Bruce A Julian and Daniel C. Cattran and Bryson Waldo and Robert Wyatt and J. Charles Jennette and Richard J Sibley and Keith Hyland and Lisa Fitzgibbons and Gladys H Hirschman and James V Donadio and Bruce John Holub},
  journal={Clinical journal of the American Society of Nephrology : CJASN},
  year={2006},
  volume={1 3},
  pages={467-74}
}
This randomized, placebo-controlled, double-blind trial evaluated the role of prednisone and omega 3 fatty acids (O3FA) in patients with IgA nephropathy. Entry criteria were (1) biopsy-proven IgA nephropathy, (2) estimated GFR > or = 50 ml/min per 1.73 m2, and (3) moderate to severe proteinuria. Thirty-three patients were randomly assigned to receive prednisone 60 mg/m2 every other day for 3 mo, then 40 mg/m2 every other day for 9 mo, then 30 mg/m2 every other day for 12 mo (prednisone group… CONTINUE READING